A Phase 2 interventional study of Anifrolumab and Placebo in Lupus Nephritis, sponsored by AstraZeneca. Completed at 80 sites in 17 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-11-24.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 114 studies in Lupus Nephritis with a site in United States — 39 open to participants now, 51 under way, 5 of them phase 3. Lupus Nephritis · United States.
Among the 114 studies in Lupus Nephritis with a site in United States, this one is the 24th largest by enrollment of the 100 interventional ones that give a count, is one of 3 that started in 2015, is one of 34 in phase 2, and was the 34th registered.
343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.
Browse Lupus Nephritis studies →39 of the 114 studies in Lupus Nephritis with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+
Pediatric Nephrology Research Consortium · Sites in United States
Ages up to 18
Hospital for Special Surgery, New York · Sites in United States
Ages 18+
iCell Gene Therapeutics · Sites in United States
Ages 16–70
Akebia Therapeutics · Sites in United States, Brazil
Ages 16+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
114 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 47 · Phase 3 17 · Phase 4 7
First in 1994; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 147 is above the median of 48 across 243 interventional studies indexed under Lupus Nephritis.
Median enrollment 50 across the 100 interventional studies, 265 across the 14 observational. Of the 53 that completed or were terminated, 31 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 114 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 6 studies filed under Lupus Nephritis — fewer than ten, so there is no comparison to draw.
11 of the studies in Lupus Nephritis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05126277Phase 3Novartis PharmaceuticalsSafety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | 2027-09-21 |
| NCT06518668Hospital for Special Surgery, New YorkA Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus | 2026-12 |
| NCT06375993Adicet TherapeuticsA Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease | 2026-12 |
| NCT06217107Morehouse School of MedicineWellness & Workforce Solution for Lupus/Lupus Nephritis | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 114 studies in Lupus Nephritis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of two doses of anifrolumab versus placebo in adult subjects with active proliferative lupus nephritis (LN).
This is a Phase 2, multicentre, multinational, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of two intravenous (IV) treatment regimens of anifrolumab versus placebo while taking standard of care (SOC) treatment with mycophenolate mofetil (MMF) and corticosteroids in adult subjects with active proliferative lupus nephritis (LN).
Main Inclusion Criteria:
Fulfils at least 4 of the 11 criteria of the revised 1982 ACR classification criteria for SLE, at least one of which must be:
Main Exclusion Criteria:
Subjects, who at the time of signing the ICF, received any of the following therapies after their qualifying biopsy
History of cancer, apart from:
During screening (within 30 days before Day 1 [Week 0 visit]), any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anifrolumab - Lower Dose
Biological: Anifrolumab
Anifrolumab - Higher Dose
Biological: Anifrolumab
Placebo IV Q4W plus SOC
Drug: Placebo
Administration every 4 week from Week 0 to Week 100 in addition to SOC which will continue until Week 112
Administration every 4 week from Week 0 to Week 100 in addition to SOC which will continue until Week 112
Change From Baseline in 24-hour Urine Protein to Creatinine Ratio (UPCR)
To evaluate the efficacy of anifrolumab plus SOC (combination of mycophenolate mofetil and corticosteroids) compared with placebo plus SOC in subjects with active proliferative lupus nephritis (LN). Geometric mean ratio of 24-hour UPCR at week 52 over baseline. Values \<1 indicate improvement from baseline.
Time frame: From Week 1 (Baseline) up to Week 52
Proportion of Subjects Achieving the Composite Endpoint Complete Renal Response (CRR)
CRR was defined as meeting all of the following: * Estimated glomerular filtration rate (eGFR) is ≥60 mL/min/1.73 m\^2 or no confirmed decrease of eGFR from baseline of ≥20% * 24-hour UPCR ≤ 0.7 mg/mg * No discontinuation of investigational product (IP) or use of restricted medication beyond the protocol allowed threshold before assessment * eGFR was based on Modification of Diet in Renal Disease (MDRD) formula. Subjects treated with restricted medication beyond the protocol allowed threshold, or discontinuing study treatment for other reasons, were regarded as non-responders.
Time frame: Week 52
Number of Subjects With Adverse Events
To assess AEs (non-serious, serious and adverse event of special interest (AESI)) as variables of safety and tolerability of anifrolimab. The AESIs are serious infections, including non-opportunistic serious infections, opportunistic infections, anaphylaxis, malignancy, herpes zoster, TB (including latent TB), influenza, vasculitis (non-SLE), and MACE (including stroke, acute coronary syndrome, myocardial infarction, or cardiovascular death). Study period: During treatment and follow-up data are presented.
Time frame: From screening (Day-30 to -1) period until the follow-up period (Week 112)
Number of Subjects With Suicidal Ideation and Behavior and Suicide Attempts Via Columbia-Suicide Severity Rating Scale (C-SSRS)
The C-SSRS was used to assess the suicidal ideation and behavior and suicide attempts on a graded scale from 1 to 5. 1 indicates as low suicidal and 5 as high suicidal behavior.
Time frame: Baseline, treatment and follow up (an average of 60 weeks)
Total Score of Personal Health Questionnaire Depression Scale-8 (PHQD-8)
PHQ-8 is a 8-item self-report scale, all items are rated on a score of 0-3, for a total range of 0-24. PHQ-8 assesses symptoms of depression over the previous 2 weeks. Higher scores indicate more depressive symptoms.
Time frame: Baseline, Week 12, Week 24, Week 36, Week 52, Week 60
Extra-renal Flares Using Systemic Lupus Erythematosus (SLE) Disease Activity Index 2000 (SLEDAI 2K) Based Flare Assessment Instrument
Flare will be defined as any one criterion present in either the Mild/Moderate Flare and/or Severe Flare categories. New or worsened manifestation should only be reported for manifestations of SLE. The SLEDAI-2K score range is 0 to 105 with higher scores representing increased disease activity. Mild/ Moderate flare defined as change in non-renal components of the SLEDAI-2K instrument score of ≥3 but \<7 points compared to previous visit. Severe Flare defined as change in non-renal components of the SLEDAI-2K instrument score by ≥7 points compared to previous visit. The flare rate per subject year is defined as the number of subjects with a respective flare divided by the sum of exposure time in days for all subjects in the analysis set multiplied by 365.25.
Time frame: From baseline up to week 112
Subjects who met all the inclusion and none of the exclusion criteria were randomized at 66 sites in 16 countries. The study was conducted from 04 November 2015 to 18 January 2021.
| Milestone | Anifrolumab - Basic Regimen | Anifrolumab - Intensified Regimen | Placebo |
|---|---|---|---|
| Started | 46 | 52 | 49 |
| Fas (full analysis set) | 45 | 51 | 49 |
| Completed | 18 | 28 | 20 |
| Not completed | 28 | 24 | 29 |
| Withdrew: Withdrawal by subject | 9 | 6 | 10 |
| Withdrew: Adverse event | 3 | 1 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 5 | 7 | 4 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Non-responding completer, not eligible for extension study, use of any restricted medications | 4 | 8 | 9 |
| Withdrew: Technical problems | 1 | 0 | 0 |
| Withdrew: Progressive disease | 1 | 0 | 2 |
| Withdrew: Physician decision | 2 | 1 | 2 |
| Withdrew: Patients did not receive ip | 1 | 1 | 0 |
To evaluate the efficacy of anifrolumab plus SOC (combination of mycophenolate mofetil and corticosteroids) compared with placebo plus SOC in subjects with active proliferative lupus nephritis (LN). Geometric mean ratio of 24-hour UPCR at week 52 over baseline. Values \<1 indicate improvement from baseline.
| milligram/milligram (mg/mg) | Anifrolumab - Basic Regimen | Anifrolumab - Intensified Regimen | All Anifrolumab | Placebo |
|---|---|---|---|---|
| Change From Baseline in 24-hour Urine Protein to Creatinine Ratio (UPCR) | 0.326 (0.190 to 0.561) | 0.285 (0.177 to 0.457) | 0.305 (0.198 to 0.468) | 0.296 (0.175 to 0.499) |
CRR was defined as meeting all of the following: * Estimated glomerular filtration rate (eGFR) is ≥60 mL/min/1.73 m\^2 or no confirmed decrease of eGFR from baseline of ≥20% * 24-hour UPCR ≤ 0.7 mg/mg * No discontinuation of investigational product (IP) or use of restricted medication beyond the protocol allowed threshold before assessment * eGFR was based on Modification of Diet in Renal Disease (MDRD) formula. Subjects treated with restricted medication beyond the protocol allowed threshold, or discontinuing study treatment for other reasons, were regarded as non-responders.
| Percentage of subjects | Anifrolumab - Basic Regimen | Anifrolumab - Intensified Regimen | All Anifrolumab | Placebo |
|---|---|---|---|---|
| Responder | 16.3 | 45.5 | 31.0 | 31.1 |
| Non-responder | 83.7 | 54.5 | 69.0 | 68.9 |
To assess AEs (non-serious, serious and adverse event of special interest (AESI)) as variables of safety and tolerability of anifrolimab. The AESIs are serious infections, including non-opportunistic serious infections, opportunistic infections, anaphylaxis, malignancy, herpes zoster, TB (including latent TB), influenza, vasculitis (non-SLE), and MACE (including stroke, acute coronary syndrome, myocardial infarction, or cardiovascular death). Study period: During treatment and follow-up data are presented.
| Participants | Anifrolumab - Basic Regimen | Anifrolumab - Intensified Regimen | All Anifrolumab | Placebo |
|---|---|---|---|---|
| Subjects with any AE- During treatment | 43 | 47 | 90 | 44 |
| Subjects with any acute AE- During treatment | 11 | 15 | 26 | 14 |
| Any AE with outcome of death- During treatment | 0 | 0 | 0 | 0 |
| Any SAE (including events with- outcome of death)- During treatment | 10 | 9 | 19 | 8 |
| Any AE leading to discontinuation of investigational product- During treatment | 5 | 6 | 11 | 5 |
| Any AE related to investigational product (investigator assessment)- During treatment | 24 | 13 | 37 | 16 |
| Any AE of severe intensity- During treatment | 6 | 7 | 13 | 8 |
| Any AESI- During treatment | 12 | 12 | 24 | 8 |
| Non-opportunistic serious infections- During treatment | 0 | 1 | 1 | 3 |
| Opportunistic infections- During treatment | 1 | 0 | 1 | 1 |
| Anaphylaxis- During treatment | 0 | 0 | 0 | 0 |
| Malignancy- During treatment | 0 | 1 | 1 | 0 |
| Herpes zoster- During treatment | 9 | 7 | 16 | 4 |
| Tuberculosis/LTB (latent tuberculosis)- During treatment | 0 | 0 | 0 | 0 |
| Influenza- During treatment | 2 | 4 | 6 | 1 |
| Vasculitis (non-systemic lupus erythematosus)- During treatment | 0 | 0 | 0 | 0 |
| Major adverse cardiovascular events according to the CV-EAC- During treatment | 0 | 0 | 0 | 1 |
| Any other significant AE- During treatment | 0 | 0 | 0 | 0 |
| Subjects with any AE- follow-up | 12 | 8 | 20 | 22 |
| Any AE with outcome of death- follow-up | 1 | 0 | 1 | 0 |
| Any SAE (including events with outcome of death)- follow-up | 3 | 0 | 3 | 3 |
| Any AE related to investigational product (investigator assessment)- follow-up | 2 | 0 | 2 | 1 |
| Any AE of severe intensity- follow-up | 2 | 0 | 2 | 3 |
| Any AESI- follow-up | 2 | 0 | 2 | 2 |
| Non-opportunistic serious infections- follow-up | 0 | 0 | 0 | 1 |
| Opportunistic infections- follow-up | 0 | 0 | 0 | 0 |
| Anaphylaxis- follow-up | 0 | 0 | 0 | 0 |
| Malignancy- follow-up | 0 | 0 | 0 | 0 |
| Herpes zoster- follow-up | 2 | 0 | 2 | 1 |
| Tuberculosis/LTB- follow-up | 0 | 0 | 0 | 0 |
| Influenza- follow-up | 0 | 0 | 0 | 0 |
| Vasculitis (non-SLE)- follow-up | 0 | 0 | 0 | 0 |
| Major adverse cardiovascular events according to the CV-EAC- follow-up | 0 | 0 | 0 | 0 |
| Any other significant AE- follow-up | 0 | 0 | 0 | 0 |
The C-SSRS was used to assess the suicidal ideation and behavior and suicide attempts on a graded scale from 1 to 5. 1 indicates as low suicidal and 5 as high suicidal behavior.
| Participants | Anifrolumab - Basic Regimen | Anifrolumab - Intensified Regimen | All Anifrolumab | Placebo |
|---|---|---|---|---|
| Suicidal attempts: Baseline | 0 | 0 | 0 | 0 |
| Suicidal attempts: Treatment | 0 | 0 | 0 | 0 |
| Suicidal attempts: Follow up | 0 | 0 | 0 | 0 |
| Suicidal behaviour: Baseline | 0 | 0 | 0 | 0 |
| Suicidal behaviour: Treatment | 0 | 0 | 0 | 0 |
| Suicidal behaviour: Follow up | 0 | 0 | 0 | 0 |
| Suicidal ideation: Baseline | 0 | 2 | 2 | 4 |
| Suicidal ideation: Treatment | 0 | 0 | 0 | 2 |
| Suicidal ideation: Follow up | 0 | 0 | 0 | 0 |
PHQ-8 is a 8-item self-report scale, all items are rated on a score of 0-3, for a total range of 0-24. PHQ-8 assesses symptoms of depression over the previous 2 weeks. Higher scores indicate more depressive symptoms.
| Score on a scale | Anifrolumab - Basic Regimen | Anifrolumab - Intensified Regimen | All Anifrolumab | Placebo |
|---|---|---|---|---|
| Baseline | 5.1 ± 4.34 | 4.3 ± 4.05 | 4.6 ± 4.18 | 5.8 ± 4.54 |
| Week 12 | 3.4 ± 3.88 | 3.1 ± 3.56 | 3.2 ± 3.68 | 5.1 ± 4.84 |
| Week 24 | 2.7 ± 2.41 | 2.5 ± 3.18 | 2.6 ± 2.86 | 4.9 ± 5.10 |
| Week 36 | 3.3 ± 4.04 | 2.5 ± 3.22 | 2.8 ± 3.63 | 3.5 ± 2.73 |
| Week 52 | 2.3 ± 3.44 | 3.4 ± 5.24 | 2.9 ± 4.51 | 4.2 ± 3.30 |
| Week 60 | 3.3 ± 4.80 | 5.6 ± 7.01 | 4.6 ± 6.06 | 4.6 ± 2.07 |
Flare will be defined as any one criterion present in either the Mild/Moderate Flare and/or Severe Flare categories. New or worsened manifestation should only be reported for manifestations of SLE. The SLEDAI-2K score range is 0 to 105 with higher scores representing increased disease activity. Mild/ Moderate flare defined as change in non-renal components of the SLEDAI-2K instrument score of ≥3 but \<7 points compared to previous visit. Severe Flare defined as change in non-renal components of the SLEDAI-2K instrument score by ≥7 points compared to previous visit. The flare rate per subject year is defined as the number of subjects with a respective flare divided by the sum of exposure time in days for all subjects in the analysis set multiplied by 365.25.
| Flare rate per subject year | Anifrolumab - Basic Regimen | Anifrolumab - Intensified Regimen | All Anifrolumab | Placebo |
|---|---|---|---|---|
| Mild/moderate: All flares | 0.019 | 0.016 | 0.017 | 0.016 |
| Mild/moderate: On-treatment | 0.017 | 0.012 | 0.014 | 0.010 |
| Mild/moderate: Off-treatment | 0.002 | 0.003 | 0.003 | 0.006 |
| Severe: All flares | 0.007 | 0.001 | 0.003 | 0.006 |
| Severe: On-treatment | 0.004 | 0.00 | 0.002 | 0.004 |
| Severe: Off-treatment | 0.003 | 0.001 | 0.002 | 0.002 |
Collected over From screening (Day-30 to -1) period until follow-up (Week 112).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Anifrolumab - Basic Regimen- Treatment Period | 0/45 (0%) | 10/45 (22.2%) | 31/45 (68.9%) |
| Anifrolumab - Intensified Regimen- Treatment Period | 0/51 (0%) | 9/51 (17.6%) | 39/51 (76.5%) |
| All Anifrolumab- Treatment Period | 0/96 (0%) | 19/96 (19.8%) | 70/96 (72.9%) |
| Placebo- Treatment Period | 0/49 (0%) | 8/49 (16.3%) | 33/49 (67.3%) |
| Anifrolumab - Basic Regimen- Follow up | 1/45 (2.2%) | 3/45 (6.7%) | 0/45 (0%) |
| Anifrolumab - Intensified Regimen- Follow up | 0/51 (0%) | 0/51 (0%) | 0/51 (0%) |
| All Anifrolumab- Follow up | 1/96 (1%) | 3/96 (3.1%) | 0/96 (0%) |
| Placebo- Follow up | 0/49 (0%) | 3/49 (6.1%) | 0/49 (0%) |
| Event | Anifrolumab - Basic Regimen- Treatment Period | Anifrolumab - Intensified Regimen- Treatment Period | All Anifrolumab- Treatment Period | Placebo- Treatment Period | Anifrolumab - Basic Regimen- Follow up | Anifrolumab - Intensified Regimen- Follow up | All Anifrolumab- Follow up | Placebo- Follow up |
|---|---|---|---|---|---|---|---|---|
| Herpes zosterInfections and infestations | 3/45 | 3/51 | 6/96 | 0/49 | 0/45 | 0/51 | 0/96 | 0/49 |
| InfluenzaInfections and infestations | 1/45 | 1/51 | 2/96 | 0/49 | 0/45 | 0/51 | 0/96 | 0/49 |
| Abscess bacterialInfections and infestations | 1/45 | 0/51 | 1/96 | 0/49 | 0/45 | 0/51 | 0/96 | 0/49 |
| Pyelonephritis acuteInfections and infestations | 1/45 | 0/51 | 1/96 | 0/49 | 0/45 | 0/51 | 0/96 | 0/49 |
| Lupus endocarditisCardiac disorders | 1/45 | 0/51 | 1/96 | 0/49 | 0/45 | 0/51 | 0/96 | 0/49 |
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 1/45 | 0/51 | 1/96 | 0/49 | 0/45 | 0/51 | 0/96 | 0/49 |
| Lupus nephritisRenal and urinary disorders | 1/45 | 1/51 | 2/96 | 1/49 | 1/45 | 0/51 | 1/96 | 0/49 |
| MalaiseGeneral disorders | 1/45 | 0/51 | 1/96 | 0/49 | 0/45 | 0/51 | 0/96 | 0/49 |
| Infusion related reactionInjury, poisoning and procedural complications | 1/45 | 0/51 | 1/96 | 0/49 | 0/45 | 0/51 | 0/96 | 0/49 |
| HypoaesthesiaNervous system disorders | 0/45 | 0/51 | 0/96 | 0/49 | 1/45 | 0/51 | 1/96 | 0/49 |
| Event | Anifrolumab - Basic Regimen- Treatment Period | Anifrolumab - Intensified Regimen- Treatment Period | All Anifrolumab- Treatment Period | Placebo- Treatment Period | Anifrolumab - Basic Regimen- Follow up | Anifrolumab - Intensified Regimen- Follow up | All Anifrolumab- Follow up | Placebo- Follow up |
|---|---|---|---|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 10/45 | 6/51 | 16/96 | 5/49 | 0/45 | 0/51 | 0/96 | 0/49 |
| DiarrhoeaGastrointestinal disorders | 3/45 | 4/51 | 7/96 | 10/49 | 0/45 | 0/51 | 0/96 | 0/49 |
| NasopharyngitisInfections and infestations | 6/45 | 9/51 | 15/96 | 9/49 | 0/45 | 0/51 | 0/96 | 0/49 |
| Upper respiratory tract infectionInfections and infestations | 8/45 | 7/51 | 15/96 | 8/49 | 0/45 | 0/51 | 0/96 | 0/49 |
| BronchitisInfections and infestations | 4/45 | 7/51 | 11/96 | 6/49 | 0/45 | 0/51 | 0/96 | 0/49 |
| Herpes zosterInfections and infestations | 6/45 | 4/51 | 10/96 | 4/49 | 0/45 | 0/51 | 0/96 | 0/49 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/45 | 3/51 | 7/96 | 4/49 | 0/45 | 0/51 | 0/96 | 0/49 |
| HeadacheNervous system disorders | 2/45 | 3/51 | 5/96 | 4/49 | 0/45 | 0/51 | 0/96 | 0/49 |
| DyspepsiaGastrointestinal disorders | 2/45 | 0/51 | 2/96 | 4/49 | 0/45 | 0/51 | 0/96 | 0/49 |
| VomitingGastrointestinal disorders | 1/45 | 1/51 | 2/96 | 4/49 | 0/45 | 0/51 | 0/96 | 0/49 |
The full analysis set included all subjects who received at least one dose of study treatment and were analyzed according to randomized treatment.
| Age, Continuous(years) | Anifrolumab - Basic Regimen | Anifrolumab - Intensified Regimen | Placebo | Total |
|---|---|---|---|---|
| Mean | 35.2 ± 11.49 | 35.0 ± 10.58 | 34.0 ± 10.18 | 34.7 ± 10.68 |
| Sex: Female, Male(Participants) | Anifrolumab - Basic Regimen | Anifrolumab - Intensified Regimen | Placebo | Total |
|---|---|---|---|---|
| Female | 37 | 45 | 38 | 120 |
| Male | 8 | 6 | 11 | 25 |
| Ethnicity (NIH/OMB)(Participants) | Anifrolumab - Basic Regimen | Anifrolumab - Intensified Regimen | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 22 | 23 | 20 | 65 |
| Not Hispanic or Latino | 23 | 28 | 29 | 80 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Anifrolumab - Basic Regimen | Anifrolumab - Intensified Regimen | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 3 | 1 | 0 | 4 |
| Asian | 11 | 7 | 10 | 28 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 |
| Black or African American | 2 | 4 | 1 | 7 |
| White | 17 | 25 | 24 | 66 |
| Other | 11 | 14 | 14 | 39 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment:
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Nov 2015 to primary completion in Nov 2019, 48 months.
Results were first posted in Nov 2021, 1 year 11 months after primary completion. A results delay was requested in Sep 2020.
Of 33 phase 2 interventional studies under Lupus Nephritis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 57. This study's 48 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Anifrolumab